Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Thumbnail
View/Open
Accepted version (912.6Kb)
Supporting information (533.9Kb)
ICR Author
Finneran, Laura
Hall, Emma
Banerji, Udai
Carreira, Suzanne
Lopez, Juanita
Kaiser, Martin
Show allShow less
Author
Hall, E
Banerji, U
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/3997
DOI
https://doi.org/10.1016/S1470-2045(20)30464-2
Collections
  • Cancer Therapeutics
  • Clinical Studies
  • Molecular Pathology
Research team
Medicine (de Bono Prostate)
Cancer Biomarkers
Clinical Pharmacology – Adaptive Therapy
Clinical Trials & Statistics Unit
ICR-CTSU Urology and Head and Neck Trials Team
Myeloma Group
Language
eng
Date accepted
2020-07-20
License start date
2020-07-20
Citation
The Lancet Oncology
Publisher
Elsevier

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.